Sign In
Sign Up
Blog
Contact

Second-Generation Antipsychotic
Renal Dose Adjustments

After managing a patient with impaired kidney function on a second-generation antipsychotic (SGA), we thought it would be helpful to have a tool to streamline the process of determining the appropriate renal dose adjustment for SGAs and selecting an SGA for a patient with compromised renal function.

Renal Dose Adjustments – A Brief Overview

Renal dose adjustments play a pivotal role in medication management. Some medications rely on the kidneys for elimination from the body. When kidney function is decreased, these medications are not cleared from the body as quickly, leading to potential accumulation and an increased risk of side effects.

Which SGAs Require Renal Dose Adjustments?

Among the SGAs, five medications require renal dose adjustments:

brexpiprazole, lurasidone, paliperidone, risperidone, and cariprazine.

For some of these medications, the recommended dose adjustments may vary depending on the dosage form. Of note, olanzapine/samidorphan is not recommended when the estimated glomerular filtration rate (eGFR) is less than 15 mL/minute/1.73 m2. However, this renal dose adjustment is based on the samidorphan component, as olanzapine does not require renal dose adjustments. Ideally, these medications would be avoided in patients with renal impairment; however, there are cases where these medications are necessary or better suited for the patient. In a real-world scenario, my patient with renal dysfunction responded well to their current antipsychotic, so we opted not to risk a relapse by changing the medication.


The table below outlines the recommendations for SGAs requiring renal dose adjustments.

Enter your patient's creatinine clearance (CrCl), and the table will show relevant dose adjustments based on your patient's renal function.

Drug CrCl (mL/min) Dose Adjustments
Brexpiprazole <60 Maximum dose:
Agitation associated with dementia due to Alzheimer disease: 2 mg once daily
Major depressive disorder: 2 mg once daily
Schizophrenia: 3 mg once daily
Cariprazine <30 Use not recommended (has not been studied)
Lurasidone <50 Initial: 20 mg daily
Maximum: 80 mg/day
Paliperidone ER Tablet 50 to <80 Initial: 3 mg daily; maximum: 6 mg daily
10 to <50 Initial: 1.5 mg daily; maximum: 3 mg daily
<10 Use not recommended
Paliperidone
(Invega Sustenna)
50 to <80 Initiation: 156 mg IM on day 1, then 117 mg IM after 7 days
Maintenance: 78 mg IM 5 weeks after initiation dose
Subsequent Maintenance Dose Maximum: 156 mg IM monthly
<50 Use not recommended
Paliperidone
(Invega Trinza)
50 to <80 Maintenance dose based on Sustenna dose
Maximum dose: 546 mg IM every 3 months
<50 Use not recommended
Paliperidone
(Invega Hafyera)
<90 Use not recommended
Risperidone Tablet 30 to 60 Do not exceed 75% of typical dose for specific indication
10 to <30 Do not exceed 50% of typical dose for specific indication
<10 Consider alternative agent
Initial: 25% of typical dose of specific indication
Titrate by 0.5 mg at the recommended frequency for the specific indication
Risperidone IM
(Risperdal Consta)
10 to ≤60 Use with caution
Initial: 12.5-25 mg IM every 2 weeks
Titrate by 12.5 mg no sooner than every 4 weeks
<10 Avoid Use, if possible
Initial: 12.5-25 mg IM every 2 weeks
Maximum dose: 25 mg IM every 2 weeks
Risperidone SubQ
(Perseris)
10 to ≤60 Use with caution (has not been studied)
<10 Avoid Use
Risperidone SubQ
(Uzedy)
10 to ≤60 Use with caution (has not been studied)
<10 Avoid Use
The Meat & Potatoes of Second-Generation Antipsychotic Renal Dose Adjustments
  1. Brexpiprazole, lurasidone, paliperidone, risperidone, and cariprazine require renal dose adjustments
  2. Renal dose adjustments and CrCl cutoffs may vary depending on dosage form

References:

  1. Invega (paliperidone) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; March 2022.
  2. Invega extended-release tablets (paliperidone) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; December 2021.
  3. Invega Sustenna (paliperidone) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; July 2022.
  4. Invega Trinza (paliperidone) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; August 2021.
  5. Latuda (lurasidone) [prescribing information]. Marlborough, MA: Sunovion Pharmaceuticals Inc; May 2022.
  6. Perseris (risperidone) [product monograph]. Etobicoke, Ontario, Canada: HLS Therapeutics Inc; May 2023.
  7. Rexulti (brexpiprazole) [prescribing information]. Rockville, MD: Otsuka America Pharmaceutical Inc; May 2023.
  8. Risperdal (risperidone) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; March 2022.
  9. Risperdal Consta (risperidone) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; February 2021.
  10. Uzedy (risperidone) [prescribing information]. Parsippany, NJ: Teva Neuroscience Inc; May 2023.
  11. Vraylar (cariprazine) [prescribing information]. Madison, NJ: Allergan USA Inc; December 2022.